Table 4. . Characteristics of patients treated with ipilimumab versus pembrolizumab.
Patient Characteristics | Ipilimumab (n = 16) | Pembrolizumab (n = 33) | p-value |
---|---|---|---|
Age | 62.63 | 64.33 | 0.691 |
Gender (% male) | 68.75% | 75.76% | 0.624 |
Overall survival (median) | 18.3 months; 95% CI: 9.2–27.4 |
21.6 months; 95% CI: 16.4–26.7 |
0.180 |
Progression-free survival (median) | 12.1 months; 95% CI: 2.9–21.24 |
19.8 months; 95% CI: 13.9–25.7 |
0.042 |